Psychiatric Drug Facts via :

“Most psychiatric drugs can cause withdrawal reactions, sometimes including life-threatening emotional and physical withdrawal problems… Withdrawal from psychiatric drugs should be done carefully under experienced clinical supervision.” Dr. Peter Breggin

Aug 31, 2012

Washington State to get $4.6 million of the $181 million from J&J

What about the primary victims?
Johnson & Johnson subsidiary to pay record amount to settle off-label marketing charges for antipsychotic drugs

Posted by Rita R. Robison on August 30, 2012 at 5:40 pm

"Attorneys general in 37 states reached a record $181 million dollar settlement with Janssen Pharmaceuticals Inc., a subsidiary of Johnson & Johnson. They allege that Janssen improperly marketed the antipsychotic drugs Risperdal, Risperdal Consta, 
Risperdal M-Tab, and Invega.

"The lawsuit charges that Janssen engaged in unfair and deceptive practices when it promoted the antipsychotic drugs for unapproved or off-label uses.

"Washington state will receive more than $4.6 million to be used for enforcement and grants that will benefit people who suffer from the conditions the drugs were illegally marketed for, Washington State Attorney General Rob McKenna said in a statement" Rita R. Robison

No offense to Ms. Robison, but the alarm on my detector is shrieking...

Ms. Robison posted this comment to her article:
"These drugs, which have serious side effects, were market(sic) for treating kids and seniors, although the drug company had no evidence the drugs were effective for these age groups." 

via Seattle Times:
Originally published Thursday, August 30, 2012 at 3:02 PM
Business Highlights
NY AG: Janssen pays $181M over drug marketing

"ALBANY, N.Y. (AP) - Janssen Pharmaceuticals Inc. and parent company Johnson & Johnson on Thursday announced a $181 million settlement with 36 states and the District of Columbia over charges of marketing anti-psychotic drugs for non-approved uses.

"New York Attorney General Eric Schneiderman, representing one of the states involved, claimed in a court filing that Janssen engaged in deceptive practices from 1998 to at least 2004 in the marketing of the drugs Risperdal, Risperdal Consta, Risperdal M-Tab and Invega. The multistate settlement comes amid a similar federal case that is still pending."

Schneiderman said the company promoted "off-label" uses of the drugs not approved by the Food and Drug Administration. For instance, Janssen is accused of promoting Risperdal, which is used to treat schizophrenia and other mental illnesses, for non-approved uses including dementia, anger management and anxiety. Janssen rewarded doctors who prescribed and promoted Risperdal for unapproved uses with lucrative consulting agreements, according to Schneiderman's complaint. 
(emphasis mine) here

I would only add, not only did the drug complany have no evidence the drugs were effective for any "off label" uses; J&J had no evidence the drugs were SAFE for children or the elderly...
I'd be a whole lot happier to read that primary victims will be helped to recover from their iatrogenic injuries...some of the victims were of them, is my son...

Does anyone besides me wonder, how many children are on Risperdal in Washington State right now? How many children are still being prescribed Risperdal (or any other neuroleptic drug) "off label"?

No comments:


Related Posts Plugin for WordPress, Blogger...

FAIR USE NOTICE: This may contain copyrighted
(C) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available for educational purposes, to advance understanding of human rights, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a 'fair use' of any such copyrighted material as provided for in Title 17 U.S.C. section 107 of the US Copyright Law. This material is distributed without profit.